- Home
- NUVL vs FMC Comparison
NUVL vs FMC Comparison
Compare NUVL & FMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- FMC
- Stock Information
- Founded
- NUVL 2017
- FMC 1910
- Country
- NUVL United States
- FMC United States
- Employees
- NUVL N/A
- FMC 5700
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- FMC Major Chemicals
- Sector
- NUVL Health Care
- FMC Industrials
- Exchange
- NUVL Nasdaq
- FMC Nasdaq
- Market Cap
- NUVL 5.4B
- FMC 5.2B
- IPO Year
- NUVL 2021
- FMC N/A
- Fundamental
- Price
- NUVL $80.48
- FMC $44.23
- Analyst Decision
- NUVL Strong Buy
- FMC Buy
- Analyst Count
- NUVL 10
- FMC 13
- Target Price
- NUVL $119.60
- FMC $51.08
- AVG Volume (30 Days)
- NUVL 582.7K
- FMC 1.9M
- Earning Date
- NUVL 08-07-2025
- FMC 07-30-2025
- Dividend Yield
- NUVL N/A
- FMC 5.25%
- EPS Growth
- NUVL N/A
- FMC N/A
- EPS
- NUVL N/A
- FMC 2.62
- Revenue
- NUVL N/A
- FMC $4,119,500,000.00
- Revenue This Year
- NUVL N/A
- FMC N/A
- Revenue Next Year
- NUVL N/A
- FMC $6.33
- P/E Ratio
- NUVL N/A
- FMC $14.43
- Revenue Growth
- NUVL N/A
- FMC 1.45
- 52 Week Low
- NUVL $55.54
- FMC $32.83
- 52 Week High
- NUVL $113.51
- FMC $68.55
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- FMC 60.38
- Support Level
- NUVL $76.27
- FMC $41.42
- Resistance Level
- NUVL $80.90
- FMC $43.66
- Average True Range (ATR)
- NUVL 2.55
- FMC 1.21
- MACD
- NUVL 0.19
- FMC 0.06
- Stochastic Oscillator
- NUVL 81.61
- FMC 89.87
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.